Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.46 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.46 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | PRNP | P04156 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5725652 | 0.98 | HPGD (0.50) | HPGDNPSR1LMNAPPARGNCOA2 | |
| SCHEMBL2160349 | 0.95 | HPGD (0.54) | HPGDNPSR1LMNAPPARGNCOA2 | |
| SCHEMBL2412998 | 0.93 | HPGD (0.50) | HPGDNPSR1LMNAPPARGNCOA2 | |
| Hydrochloric Acid SCHEMBL2410455 | 0.92 | HPGD (0.49) | HPGDNPSR1LMNAPPARGNCOA2 | |
| SCHEMBL7211399 | 0.85 | HPGD (0.54) | HPGDNPSR1LMNAPPARGNCOA2 | |
| SCHEMBL2162296 | 0.85 | HPGD (0.52) | HPGDNPSR1LMNAPPARGNCOA2 | |
| SCHEMBL2162982 | 0.84 | HPGD (0.55) | HPGDNPSR1LMNAPPARGNCOA2 | |
| SCHEMBL317871 | 0.84 | HPGD (0.55) | HPGDNPSR1LMNAPPARGNCOA2 | |
| SCHEMBL2162352 | 0.84 | HPGD (0.51) | HPGDNPSR1LMNAPPARGNCOA2 | |
| SCHEMBL27621806 | 0.84 | HPGD (0.55) | HPGDNPSR1LMNAPPARGNCOA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2528908-B1 | THERAPEUTIC AGENTS FOR TREATMENT OF OCULAR HYPERTENSION | ALLERGAN INC (US) | 2019-03-13 | — | — | EP | disclosed |
| US-9090584-B2 | Therapeutic agents for treatment of ocular hypertension | ALLERGAN, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| EP-2528908-A1 | THERAPEUTIC AGENTS FOR TREATMENT OF OCULAR HYPERTENSION | Allergan, Inc. (US) | 2012-12-05 | — | — | EP | disclosed |
| WO-2011094231-A1 | THERAPEUTIC AGENTS FOR TREATMENT OF OCULAR HYPERTENSION | ALLERGAN, INC. (US) | 2011-08-04 | — | — | WO | disclosed |
| US-20110184055-A1 | THERAPEUTIC AGENTS FOR TREATMENT OF OCULAR HYPERTENSION | ALLERGAN, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| US-7442702-B2 | Treatment of bone disorders; carboxy derivatives | PFIZER INC. (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1021410-B1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER (US) | 2006-12-27 | — | — | EP | disclosed |
| EP-0946501-B1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER (US) | 2006-05-31 | — | — | EP | disclosed |
| US-6998423-B2 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | PFIZER INC. (US) | 2006-02-14 | — | — | US | disclosed |
| EP-1601351-A1 | USE OF EP2 SELECTIVE RECEPTOR AGONISTS IN MEDICAL TREATMENT | Pfizer Products Inc. (US) | 2005-12-07 | — | — | EP | disclosed |
| US-6124314-A | A PROSTAGLANDIN AGONISTS FOR TREATING VERTEBRATE BONE DISORDERS | PFIZER INC. (US) | 2000-09-26 | — | — | US | disclosed |
| EP-1021410-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 2000-07-26 | — | — | EP | disclosed |
| EP-1000619-A2 | Method for treating glaucoma | Pfizer Products Inc. (US) | 2000-05-17 | — | — | EP | disclosed |
| EP-0946501-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1999-10-06 | — | — | EP | disclosed |
| EP-0911321-A2 | Compounds for the treatment of osteoporosis | PFIZER INC. (US) | 1999-04-28 | — | — | EP | disclosed |
| WO-1999019300-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 1999-04-22 | — | — | WO | disclosed |
| WO-1998028264-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1998-07-02 | — | — | WO | disclosed |
| US-5166218-A | Antilipemic agents or antiglycemic agents | HOFFMANN-LA ROCHE INC. (US) | 1992-11-24 | — | — | US | disclosed |
| US-5064863-A | Catabolic activity, obesity, diabetes | HOFFMANN-LA ROCHE INC. (US) | 1991-11-12 | — | — | US | disclosed |
| US-4652679-A | Aziridine and phenethanolamine derivatives having antiobesity and anti-hyperglycaemic acitivity | HOFFMANN-LA ROCHE INC. (US) | 1987-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184055-A1 | THERAPEUTIC AGENTS FOR TREATMENT OF OCULAR HYPERTENSION | PTGIR, PTGIS, AGTR2 | HPGD 98/4885NPSR1 1074/4885LMNA 3581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.